Cost-Based Price Calculation of Mexiletine for Nondystrophic Myotonia-Reference-Cited by-同舟云学术

Cost-Based Price Calculation of Mexiletine for Nondystrophic Myotonia

Published:2021-07 Issue:7 Volume:24 Page:925-929
ISSN:1098-3015
Container-title:Value in Health
language:en
Short-container-title:Value in Health

Author:

van den Berg Sibren,van der Wel Vincent,de Visser Saco J.,Stunnenberg Bas C.,Timmers Lonneke,van der Ree Martijn H.,Postema Pieter G.,Hollak Carla E.M.

Publisher

Elsevier BV

Subject

Public Health, Environmental and Occupational Health,Health Policy

Reference18 articles.

1. Combined N-of-1 trials to investigate mexiletine in non-dystrophic myotonia using a Bayesian approach: study rationale and protocol;Stunnenberg;BMC Neurol,2014

2. Treatment of ventricular arrhythmias with mexiletine (Kö 1173);Talbot;Lancet,1973

3. 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death the Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the Europea;Priori;Eur Heart J,2015

4. Myotonia with muscular weakness corrected by exercise: the therapeutic effect of mexiletine. Article in French;Pouget;Rev Neurol,1983

5. Trip J, Drost GG, van Engelen BG, Faber CG. Drug treatment for myotonia. Cochrane Database Syst Rev. Published Online First: January 25, 2006. https://doi.org/10.1002/14651858.CD004762.pub2.

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Chronic Mexiletine Administration Increases Sodium Current in Non-Diseased Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes;Biomedicines;2024-05-29

2. The temporalities of prices: ‘Value-based pricing’ in pharmaceutical markets;Economy and Society;2024-04-02

3. Financing repurposed drugs for rare diseases: a case study of Unravel Biosciences;Orphanet Journal of Rare Diseases;2023-09-12

4. Combatting the rising costs of cancer drugs; interventions from a university hospital’s perspective;Frontiers in Pharmacology;2023-08-28

5. Drug repurposing in skeletal muscle ion channelopathies;Current Opinion in Pharmacology;2023-02